EU approves Arrowhead's plozasiran for rare triglyceride disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
June 22, 2026 12:33 PM EDTREDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of lifeMarketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placebo
PASADENA,... More
